PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

Ítems similars

• Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours
  per: Mahalingam, Devalingam, et al.
  Publicat: (2020)
• Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
  per: Tang, Xue-miao, et al.
  Publicat: (2017)
• A National Survey of Medical Oncologist’s Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab
  per: Lowe, Kimberly A., et al.
  Publicat: (2019)
• Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
  per: Pietrantonio, Filippo, et al.
  Publicat: (2019)
• Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
  per: Kurreck, A., et al.
  Publicat: (2020)